Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences:
- Guggenheim Healthcare Talks: 2021 Genomic Medicines and Rare Disease on April 1, 2021, where at 10:00 a.m. EDT, Chief Executive Officer, Theresa Heggie will participate in a panel discussion, titled ‘The low hanging fruit in gene therapy might be hard to reach – Challenges for Hemophilia A and B.’
- 20th Annual Needham Virtual Healthcare Conference on April 13, 2021 where Theresa Heggie will present a Company overview at 8:00 a.m. EDT.
Webcasts of both the panel discussion and the Company presentation will be available on the investor relations section of the Freeline website at Freeline.life.